Trial · NCT00738699
Adverse events412
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 412
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 132 | 279 | |
| other | Nausea | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 66 | 133 | |
| other | Diarrhoea | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 119 | 279 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 53 | 133 | |
| other | Constipation | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 96 | 279 | |
| other | Constipation | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 53 | 133 | |
| other | Abdominal pain | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 88 | 279 | |
| other | Abdominal pain | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 34 | 133 | |
| other | Vomiting | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 84 | 279 | |
| other | Vomiting | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 37 | 133 | |
| other | Abdominal Distension | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 51 | 279 | |
| other | Abdominal Distension | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 21 | 133 | |
| other | Ascites | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 22 | 279 | |
| other | Ascites | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 11 | 133 | |
| other | Stomatitis | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 26 | 279 | |
| other | Stomatitis | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 7 | 133 | |
| other | Dyspepsia | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 22 | 279 | |
| other | Dyspepsia | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 10 | 133 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | MORAb-003 (Farletuzumab) Plus Paclitaxel | 25 | 279 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Placebo (Normal Saline) Plus Paclitaxel | 6 | 133 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00738699/events